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Role of Glucocorticoids in Hearing 




During the last 15 years, cochlear implantation became available as a method of 
treatment for different types of hearing impairment. Leading, specialized centers 
have now introduced the analysis of the nonsurgical factors that could contribute 
to improve rates of hearing preservation in preoperative period, during surgery, 
or in postoperative period in patients who suffer from partial deafness. One of 
the approaches is using pharmacotherapy (glucocorticoids) as a factor that may 
improve hearing functions. Preservation of hearing in patients who suffered 
from partial deafness and underwent cochlear implantation by using two differ-
ent regimes of corticosteroid therapy was the aim of the study carried out by the 
World Hearing Center (WHC). Forty-six patients were enrolled in the trial and 
divided into three subgroups. Hearing preservation (HP) was evaluated using 
pure tone audiometry (PTA) (11 frequencies ranging from 125 to 8000 Hz). The 
impact of administrated substances was evaluated by pure tone audiometry during 
six different periods: before cochlear implant surgery, during activation of audio 
processor, and 1, 6, 9, and 12 months after activation of audio processor in com-
parison with control group. According to hearing preservation (HP) classification, 
patients from the second group, to whom combined glucocorticoid therapy was 
administrated, achieved the best HP results. The complete hearing preservation 
index was observed in the highest percentage of patients from the second subgroup. 
The dispersion of measured values was lesser than in other subgroups. According 
to the results, administration of glucocorticoids (dexamethasone and prednisone 
or dexamethasone only) to the patients, who suffered from partial deafness and 
underwent cochlear implantation surgery, may be important in stabilization of 
hearing thresholds and in protection of hearing.
Keywords: glucocorticoids, dexamethasone, prednisone, partial deafness treatment, 
cochlear implant
1. Introduction
In the past cochlear implantation was a “gold standard” treatment method for 
patients who suffer from hearing impairment and dedicated only for patients totally 
deaf. During the last 15 years, cochlear implantation became available also as a 
treatment for different types of hearing impairment. Regardless of surgical tech-
nique for cochlear implantation (cochleostomy or an approach through the round 
window), specialized centers have now introduced the comprehensive analysis of 
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the nonsurgical factors that could contribute to improve rates of hearing preserva-
tion in preoperative, during surgery, or in postoperative period in patients who suf-
fer from partial deafness. One of the approaches of many leading research centers 
is using pharmacotherapy (glucocorticoids) as a factor which may improve hearing 
functions following cochlear implantation [1, 2]. Glucocorticoids play an important 
role in pharmacotherapy of many different otorhinolaryngological diseases, such 
as Meniere’s disease, sudden sensorineural hearing loss (SSNHL), and tinnitus, and 
as a part of otorhinolaryngological procedures in surgeries (e.g., cochlear implanta-
tion) [3, 4]. The effects of treatment listed diseases are different and mainly depend 
on treatment results, adverse effects of used medications, and additional pharma-
cological treatment that was used during treatment. Unfortunately, the side effects 
of glucocorticoids are serious, and as the result, sometimes pharmacotherapy has to 
be stopped, and discontinuation of therapy is the only solution.
On the one hand, insertion of specific electrode of cochlear implant requires 
perfection in surgical techniques, but on the other it is difficult to do perfectly. 
Clinically approved algorithm of corticosteroid therapy (local or systematic) is 
discussed as one factor in reducing oxidative stress, an inflammatory reaction, and 
as a result apoptosis of hearing cells. A major challenge in effective administration 
and delivery medicines is the blood-labyrinth barrier (BLB) and physical inaccessi-
bility of the inner ear, especially the apical part of the cochlea. It seems to be crucial 
especially for patients who suffer from partial deafness (PD) (apical hair cells are 
responsible for receiving low frequencies).
1.1 Characteristic: glucocorticoids
The adrenal cortex synthesizes two classes of steroids: corticosteroids (min-
eralocorticoids and glucocorticoids) and androgens. One of the differences is the 
number of carbon atoms. Corticosteroids have 21 carbon atoms, and androgens 
have 19 carbon atoms. In the human body, the main glucocorticoid is cortisol, and 
the main mineralocorticoid is aldosterone [5].
Glucocorticoid receptor (GR) is located in the cytoplasm in inactive form until it 
binds with the molecule of glucocorticoid. This action results in activation of recep-
tor and translocation complex: glucocorticoid receptor for glucocorticoid to the nucleus. 
Activation of receptor is based on dissociation from the associated proteins. After 
translocation to the nucleus, a complex of glucocorticoid receptor interacts with 
specific, short DNA sequences with the regulatory regions. The regions are termed 
glucocorticoid responsive elements (GREs) and allow induction of the gene transcrip-
tion by glucocorticoids. This process is very complicated because of interaction 
with specific cofactors and proteins and still not well and completely understood 
by scientists and researchers [5]. Not only positive response to glucocorticoid 
is possible. According to Webster and Cidlowski, genes negatively regulated by 
glucocorticoids were also identified [6]. An example of downregulation (negative 
regulation) is to repress the expression of gene responsible for encoding cytokines 
or enzymes (e.g., collagenase). Both play an important role in inflammatory and 
immune reactions. According to the information provided, this negative expression 
appears to play a key function in anti-inflammatory and immunosuppressive effects 
of the glucocorticoids. Anti-inflammatory activity of representative glucocorti-
coids is presented below (Table 1). Dexamethasone and betamethasone are two 
glucocorticoids with the highest anti-inflammatory activity. If cortisol has anti-
inflammatory activity defined as 1, then prednisone, prednisolone, triamcinolone, 
and 6α-methylprednisolone have 4–5 times stronger anti-inflammatory properties, 
with longer half-life than cortisol. Examples of representative glucocorticoids and 
their properties are shown in Table 1.
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1.2 Functions and activity of glucocorticoids
The two key roles glucocorticoids play as biological and pharmaceutical com-
pounds are anti-inflammatory and immunosuppressive roles. Glucocorticoids also 
affect:
1. Carbohydrate and protein metabolism. Glucocorticoids stimulate the liver 
to form glucose in biochemical reaction (gluconeogenesis) from amino acids 
and glycerol or/and stimulate the liver to release glucose from glycogen. At 
the same time, the diminishing of glucose is reduced, reaction of lipolysis 
and protein breakdown increases, and as a result the blood glucose level rises. 
Patients suffering from diabetes or other forms of hyperglycemia during 
glucocorticoid therapy should be under special control. Glucocorticoids induce 
increased protein metabolism and deliver compounds such as amino acids for 
further reactions.
2. Lipid metabolism. One effect of therapy with corticosteroids is redistribution 
of fat tissue known as Cushing’s syndrome.
3. Water and electrolyte balance. Glucocorticoids exert negatively on metabolism 
of Ca2+ due to reduction of absorption from the digestive system and increased 
excretion via kidneys. Prophylaxis of osteoporosis requires supplementa-
tion of Ca2+ ions and physical activity adequate to possibilities of patient. 
Additionally, glucocorticoids reduce activity of osteoclasts and stimulate the 
activity of osteoblasts. Glucocorticoid therapy sometimes may cause increased 
retention of Na+ ions and decrease in concentration of K+ ions because of 
interaction with receptor for mineralocorticoids. The deterioration in ion level 
may affect the cardiovascular system.
4. Impaired wound healing. Due to reduction of synthesis of collagen, glycosami-
noglycans and disturbance in fibroblast function problem with healing wound 
may occur.
5. Anti-inflammatory and immunosuppressive activity. Glucocorticoids can 
suppress or prevent inflammatory reactions in different ways: reduction in 
diapedesis of granulocytes and proliferation of lymphocytes Th, inhibition/
Anti-inflammatory activity Biological half-life t1/2 (h)
Cortisol 1 Short: t1/2 = 8–12
Cortisone 0.8 Short: t1/2 = 8–12
Fludrocortisone 10 Intermediate: t1/2 = 12–36
Prednisone 4 Intermediate: t1/2 = 12–36
Prednisolone 4 Intermediate: t1/2 = 12–36
6α-methylprednisone 5 Intermediate: t1/2 = 12–36
Triamcinolone 5 Intermediate: t1/2 = 12–36
Betamethasone 25 Long: t1/2 = 36–72
Dexamethasone 25 Long: t1/2 = 36–72
Table 1. 
Characteristics of representative corticosteroids [5].
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reduction of activation of macrophages, neutrophils, mast cells and cytokines 
(interleukins 1, 2, 3, 4, 5, 6, 8), and tumor necrosis factor alpha (TNF-α); 
reduction in the expression of cyclooxygenase 2 (COX-2) resulting in drop-
ping of production of a few prostanoids; intensification of activity of catechol 
amines; and reduction in production of histamine by basophils [7, 8].
Sometimes glucocorticoid treatment in the otorhinolaryngological diseases 
requires high doses or long time of therapy. It may cause adverse effects. Some of 
them are listed below:
1. Repression in responding on infections and injuries
2. Propensity to opportunistic infections
3. Propensity to hyperglycemia
4. Muscular dystrophy
5. Cushing’s syndrome
6. Glaucoma (mostly in patients genetically predisposed)
7. Osteoporosis
Acute discontinuation of treatment may cause adrenocortical insufficiency, 
especially when therapy was long-term. It is important to reduce the dose of gluco-
corticoids slowly, not suddenly [5].
1.3 Pharmacokinetics of glucocorticoids and studies on animal model
Many factors have an impact on pharmacokinetics of drugs. Pharmacokinetics is 
described by acronym LADME (liberation, absorption, distribution, metabolism, and 
elimination). Firstly, the therapeutic (or its carrier) must be water-soluble, because 
of distribution in the blood. The protein binding of drugs is one of the key factors 
in initial parts in pharmacokinetic process. The greater the protein binding of drug 
is, the longer the activity of therapeutic due to its function as a stock of drug in the 
organism. Absorption depends on lipophilicity and solubility of drugs. According 
to the data and publications, only a few medical substances can effectively be used 
in otorhinolaryngological practice due to achieving sufficient concentration in the 
inner ear [9]. Two main groups of drugs are used in clinical practice: aminoglyco-
side (mainly gentamicin) in pharmacotherapy of Meniere’s disease [10] and cortico-
steroids (dexamethasone, triamcinolone and dexamethasone) in pharmacotherapy 
of idiopathic sudden sensorineural hearing loss (ISSHL) and other cases of acute hear-
ing loss [11]. The inner ear from a pharmacokinetic point of view is a multicom-
partment model [12, 13] with stable fluids and balance between them (due to the 
presence of blood-labyrinth barrier (BLB)). Distribution process depends on many 
different factors such as route of administration, model of administration (single or 
repeated administration), dose of medicine, ionic composition, and pH or osmolar-
ity of solution. The same factors of drug chemical and physical properties influence 
the elimination of drug from the organism (clearance, rate of removal).
In a study published in 2017, authors in animal model (guinea pig) compared 
dexamethasone with saline. Both substances were administrated intrave-
nously 60 min before implantation. As a final conclusion, authors stressed that 
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dexamethasone could reduce scarring process as the electrode negotiated the hook 
region or near the electrode tip, but they did not observe the relation between dexa-
methasone and reduction of fibrosis relating to cochleostomy [13]. In vitro studies 
showed the correlation between reduction (loss) of auditory cells after exposure to 
tumor necrosis factor alpha (TNF-alpha) and dexamethasone-releasing polymer used 
to coat electrode of cochlear implant carries.
Research carried out on animal model proved that prolonged steroid therapy 
could significantly improve hearing preservation rate (including pharmacoki-
netic and morphological analysis) when the electrode of cochlear implants was 
covered with dexamethasone (special formulation with controlled drug release) 
[14]. However, Honeder et al. did not confirm that steroids could have a positive 
impact on residual hearing in a guinea pig model. One reason why both authors 
gain different results may lie in different types of steroid therapy. In the first study, 
dexamethasone was used on the contrary to the second study where triamcinolone 
was administrated [15]. Douchement et al. investigated the effects of steroids using 
a gerbil animal model. Animals were implanted with an electrode with controlled 
dexamethasone delivery (1 and 10% concentration of dexamethasone) on one 
side and a conventional electrode on the contralateral side. Hearing levels were 
established based on the tone bursts on auditory brain stem responses at 4–6-week 
postimplantation and at 1-year postimplantation period for older gerbils. A 1-year 
observation period showed significantly improved results obtained for the high 
auditory frequencies, but the results for the low frequencies were ambiguous [16].
Cho et al. analyzed the efficacy of preoperative and intraoperative schemes of 
administration of steroids for hearing preservation. Dexamethasone was administrated 
systematically at the dose of 5 mg/ml in the preoperative period and then topically 
(off-label) during cochlear implantation surgery. Pure tone audiometry (PTA) was 
measured in four frequencies: 250, 500, 1000, and 2000 Hz. Statistically significant 
differences were observed between the steroid group and the control group, supporting 
the observation and beneficial impact of administration steroid treatment [17].
1.4 Glucocorticoid administration: the possibilities
During treatment of otologic diseases, two routes of administration of glucocor-
ticoids are possible: local and systemic. Local administration (e.g., transtympanic 
injection) allows to achieve high concentration of glucocorticoid in the middle ear, 
but due to presence of Eustachian tube, the medication may be partly evacuated. 
Local drug administration to the middle and inner ear avoids “the first pass effect.” 
The main advantages of local drug delivery are as follows:
1. Reduction dose of medicine
2. Achieving high concentration
3. Better effects of treatment
4. Reducing possibility of adverse effects
5. Bypassing of the blood-labyrinth barrier (BLB)
Local drug administration may involve intracochlear administration (e.g., stem 
cell, gene therapy) or extracochlear administration (e.g., intratympanic injection). A 
combination of both routes of drug delivery to the ear is also possible [13]. According 
to publications, systemic administration in treatment of otorhinolaryngological 
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diseases is known as noninvasive route of drug delivery, due to lack of damaging of 
tympanic membrane. Adverse effects of systemic delivery may be one of the purposes 
of discontinuation of the therapy. The presence of blood-labyrinth barrier (BLB) in the 
inner ear is one of the causes of problems with reaching high concentration of drug.
1.5 The experience in using glucocorticoids in PDT patients
This study was the first study which was carried out in the Institute of 
Physiology and Pathology of Hearing World Hearing Center and will be continued 
with different groups of patients and different implants and algorithms of gluco-
corticoid administration. The aim of the study was to evaluate different regimes of 
administration of glucocorticoids: dexamethasone and dexamethasone/prednisone 
to partial deafness treatment (PDT) patients who underwent cochlear implantation 
on the hearing preservation. Implant used in the study was the MED-EL implant 
with an electrode length of 28 mm (Flex 28). The impact of administrated glucocor-
ticoids on hearing was measured in six different periods:
1. Preoperatively
2. During activation of audio processor
3. One month after activation of audio processor
4. Six months after activation of audio processor
5. Nine months after activation of audio processor
6. One year (12 months) after activation of audio processor
Forty-six patients were enrolled to the trial and then divided randomly into three 
subgroups. Patients from the first subgroup underwent intravenous steroid therapy 
(Figure 1). According to the scheme, 30 min before implantation, dexamethasone 
at the dose of 0.1 mg/kg body mass was administrated intravenously to patients 
from the first subgroup. For the next 3 consecutive days in every 12 h, dexametha-
sone was administrated intravenously at the same dose to each patient.
Patients from the second subgroup underwent prolonged (combined) steroid 
therapy: oral and intravenous. Three days prior to the surgery, prednisone was 
administrated orally at a dose of 1 mg/kg body mass/day. Then, 30 min before the 
cochlear implantation surgery, dexamethasone was administrated intravenously at a 
dose of 0.1 mg/kg body mass. For the next 3 consecutive days in every 12 h, dexa-
methasone was administrated intravenously (the same as in the first subgroup). For 
the next 3 days, prednisone was administrated orally at the dose of 1 mg/kg body 
mass/day. After this period, the dose of prednisone was reduced (10 mg per every 
Figure 1. 
Scheme of steroid administration in the first subgroup of patients.
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day) till complete reduction of dose, due to reducing the risk of adverse effects. The 
algorithm of administration of glucocorticoids to patients form the second sub-
group is presented below (Figure 2).
The third subgroup was a control group and underwent standard cochlear 
implantation procedure [18].
1.6 Administrated glucocorticoids
According to the protocol of this study, two different algorithms of administra-
tion with two different glucocorticoids were proposed in the study. Although both 
substances belong to the same pharmacological group, both of them have dif-
ferent pharmacokinetics and pharmacodynamic properties. Dexamethasone is a 
synthetic glucocorticoid (molecular weight 392.46 g/mol) with anti-inflammatory, 
anti-allergic, and immunomodulating activity. In common practice dexametha-
sone is administrated intravenously or off-label, e.g., transtympanic injections. After 
intravenous administration the mean time to peak concentration (Cmax) is between 
10 and 30 min, and the half-life (t1/2) is from 2.2 to 3.8 h. Transport proteins 
are responsible for transport and distribution of dexamethasone in blood. 
Dexamethasone is mainly metabolized by the liver and eliminated with the bile. 
Only 2.6% of the chemically unchanged dose is eliminated via kidneys.
Prednisone is a synthetic glucocorticoid (derivative of cortisone) and classified 
according to the Anatomical Therapeutic Chemical (ATC) Classification System as 
H02 AB 07. Prednisone is prodrug which converts into active metabolite—predniso-
lone (higher anti-inflammatory activity). According to characteristic of medical 
product and literature data, bioavailability of prednisone administrated orally is 
between 70 and 90%. The mean time to peak concentration (Cmax) is between 1 and 
2 h. Half-life (t1/2) is between 3.4 and 3.8 h in plasma and 18–36 h in tissue. Binding 
prednisone with plasma proteins is between 70 and 73% (binding prednisolone 
(active metabolite) to the plasma proteins is higher (90–95%)). Similar to dexa-
methasone, prednisone is metabolized mainly by the liver and eliminated with the 
bile. Pharmacodynamic and pharmacokinetic data were based on characteristics of 
medical products: dexamethasone and prednisone.
1.7  Methodology of the study: primary and secondary outcomes and inclusion 
and exclusion criteria
The primary outcome variables were mean values of hearing thresholds aver-
aged across all 11 frequencies (125–8000 Hz). The secondary outcome variable 
was hearing preservation (HP). Hearing preservation (HP) was calculated by 
comparing hearing thresholds in the 1-year postoperative period with the preop-
erative hearing thresholds, according to the hearing preservation (HP) formula 
(below) and converted to three levels: minimal, partial, and complete hearing 
preservation.
Figure 2. 
Scheme of steroid administration in the second subgroup of patients.
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  (1)
In this equation, PTApre is the pure tone average measured preoperatively, 
PTApost is the pure tone average measured postoperatively, and PTAmax is the 
maximal sound intensity generated by a standard audiometer, usually 120 dB hear-
ing level (HL), and HP is the rate of hearing preservation in percentage [19].
The protocol of this prospective clinical trial was approved by the Bioethics 
Commission. Patients enrolled to the study suffered from severe-to-profound 
hearing loss and were classified according to Prof. H. Skarżyński partial deafness 
treatment (PDT) classification into two groups: partial deafness treatment-electrical 
stimulation (PDT-EC) and partial deafness treatment-electroacoustic stimulation 
(PDT-EAS) (Figure 3) [20, 21].
Inclusion and exclusion criteria were in accordance with the consensus of the 
international HEARRING group on hearing preservation in cochlear implant. Study 
eligibility criteria included participants ≥18 years of age with a cochlear duct length 
of ≥27.1 (measured by computer tomography), with:
1. Hearing sound levels in the range of 10–120 decibels (dB) and sound 
 frequencies of 125–250 hertz (Hz)
2. Hearing sound levels of 35–120 dB and frequencies of 500–1000 Hz
3. Hearing sound levels of 75–120 dB and frequencies of 2000–8000 Hz [18]
Exclusion criteria included suffering from severe diseases when the steroid 
treatment could worsen the patient’s condition or when there would be a possibility 
of interaction between medication intake by patients and steroids. Nonparametric 
tests were used in the study due to discrepancies in the number of participants 
between all subgroups, small number of participants in the study, and violation of 
normal distribution of pure tone audiometry results [18].
1.8 Main results and observations
Preoperative hearing threshold levels of patients from the first, the second, 
and the control subgroup were similar. The difference between patients from 
the three subgroups was not statistically significant, which means that hearing 
Figure 3. 
Partial deafness treatment groups for cochlear implantation. ENS, electro-natural stimulation; EC, electrical 
complement; EAS, electrical-acoustic stimulation; ES, electrical stimulation.
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thresholds in preoperative period of all participants, who were enrolled to the 
study, were similar.
The deterioration of average hearing thresholds (measured by pure tone audi-
ometry) was observed from the first point of observation—the activation period. A 
significant difference was observed between two groups: patients from the second 
subgroup (combined steroid therapy, prednisone + dexamethasone) and the con-
trol subgroup. Patients from the second subgroup had better pure tone audiometry 
(PTA) results considering low frequencies in comparison with the results of patients 
from the control group. Similar observation was done in 1, 6, 9, and 12 months after 
activation follow-up periods. The results of the study may be even more a promise 
and beneficial for patients. The hearing of participants of the study, to whom 
combined (prolonged) glucocorticoid therapy was administrated, remained stable 
during all observed follow-up periods (activation, 1-month, 6-month, 9-month, and 
12-month post-activation follow-ups), and they did not vary significantly (Figure 4).
The hearing preservation (HP) rate is calculated using hearing preservation 
formula by comparing hearing threshold in the 12-month postoperative period with 
the preoperative hearing thresholds. Then the results were divided, according to the 
hearing preservation (HP) formula, into minimal HP, partial HP, and complete HP 
according to Table 2. The smallest variability of results was observed in the second 
subgroup (patients to whom prednisone and dexamethasone were administrated) 
as well as the highest overall HP rate. Patients from the second subgroup (prolonged 
steroid therapy) and nearly 69% of the patients from the first subgroup had partial 
or complete hearing preservation. The majority of patients from the control group 
had minimal hearing preservation (Table 2 and Figure 5).
1.9 Final conclusion
This study is the first study to report the results of two different regimes of 
steroid administration in human subjects who underwent cochlear implantation in 
comparison with the control group. As it was said in the previous paragraph, the 
findings of this study have shown that glucocorticoid therapy not only stabilizes 
hearing thresholds but also preserves hearing ability in adult patients. The combina-
tion of intravenously administrated dexamethasone and orally administrated pred-
nisone in one scheme of administration seems to be the optimal treatment regimen. 
Figure 4. 
Mean hearing thresholds of patients with standard steroid therapy (subgroup No 1), patients with prolonged 
steroid therapy (subgroup No 2), and control patients (subgroup No 3) in the preoperative period, upon 
activation, and at 1-month, 6-month, 9-month, and 12-month follow-up after CI implantation.
The Human Auditory System - Basic Features and Updates on Audiological Diagnosis and Therapy
10
Previously published studies have shown that there have been new directions in the 
development and use of electrodes and cochlear implant surgery in recent years. 
Currently, researchers, clinicians, and commercial companies are working on devel-
oping modern steroid-eluting electrodes or electrodes with controlled drug deliv-
ery. The results of the preliminary study described in this chapter suggested that 
combined glucocorticoid administration (according to scheme of administration in 
the second subgroup) is beneficial in preserving and stabilizing hearing thresholds 
in patients undergoing cochlear implantation surgery. The findings of this study 
are supported by the results of similar studies [1, 17]. However, the present study 
adds to the findings of previous studies by having a relatively long follow-up period, 
of 12 months after activation, with study analysis conducted during six different 
follow-up periods. According to the results, administration of glucocorticoids 
(dexamethasone and prednisone or dexamethasone only) to the patients, who 
suffered from partial deafness and underwent cochlear implantation surgery, may 
be important in stabilization of hearing thresholds and in protection of hearing. 
The dispersion of measured values in the second group (the second subgroup) was 
lesser than in the first and the control group.
Figure 5. 
Hearing preservation (HP) rate in three subgroups.
Minimal (0–25%) Partial (26–75%) Complete (≤75%)
Subgroup No 1 5 (31.2) 7 (43.8) 4 (25.0)
Subgroup No 2 0 (0.0) 8 (61.5) 5 (38.5)
Control group 12 (70.6) 3 (17.6) 2 (11.8)
Table 2. 
Hearing preservation 12 months after CI implantation, according to the type of treatment (data are given as 
the number of patients (percentage in brackets).
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